Herperax, ointment 5% 5 g

Antiviral agent for external use, synthetic analog of purine nucleoside. Thymidine kinase of virus-infected cells actively converts acyclovir through a series of sequential reactions into acyclovir mono-, di- and triphosphate.

Indications

Treatment of viral infections caused by the herpes simplex virus (Herpes simplex) of the lips and facial skin (recurrent herpes of the lips).

Pharmacological effect

Pharmacotherapeutic group

Special instructions

Acyclovir ointment is effective for preventing relapses of herpes of the lips and face.
It is not recommended to use on the mucous membranes of the mouth, eyes and vagina. Do not use for the treatment of genital herpes. Avoid getting the ointment in your eyes.

In case of severe manifestations of recurrent herpes, it is recommended to consult a doctor.
Patients with herpes labialis should avoid transmitting the virus, especially if active lesions are present.
The earlier it is started (at the first signs of infection), the higher the effectiveness of treatment.

To realize the therapeutic effect of acyclovir, the state of the body’s immune system is important. Patients with immunodeficiency conditions are not recommended to use Herperax, ointment for external use. Such patients should follow the doctor’s recommendations when treating any infectious diseases.

Patients with renal and hepatic insufficiency Despite the fact that acyclovir is mainly excreted by the kidneys, the systematic absorption of acyclovir after external use is insignificant. Accordingly, there is no need to change the dose in patients with renal or hepatic impairment.

Impact on the ability to drive vehicles and machinery
The drug Herperax does not affect the ability to drive or engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Acyclovir

Composition

1 g of ointment contains:

Active substance – acyclovir 50 mg

Excipients – macrogol 4000 – 207.0 mg, macrogol 1540 – 40.0 mg, macrogol 400 – 695.0 mg.

Pregnancy

Pregnancy
Use is only possible when the expected benefit outweighs the potential and unknown risk, but systemic exposure with topical application of the ointment is very low.
As a result of post-registration experience with the use of acyclovir, data were obtained containing information on the results of pregnancy in women receiving acyclovir in any dosage form. In an analysis of registry data, there was no increase in the number of birth defects in infants whose mothers took acyclovir during pregnancy compared with the general population. The identified birth defects were not uniform or consistent, suggesting a common cause.
However, caution should be exercised when prescribing the drug during pregnancy and assess the expected benefit to the mother and the possible risk to the fetus.

Breastfeeding period
Limited data indicate that the drug passes into breast milk with regular use. However, the dosage received by a breastfed infant will be negligible.

Contraindications

Hypersensitivity to acyclovir, valacyclovir, polyethylene glycol.

With caution
Pregnancy, breastfeeding period.

Side Effects

The incidence of side effects is classified by organ system and frequency in accordance with the recommendations of the World Health Organization (WHO): very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (≥1/10,000, <1/1000) and very rare (<10,000).From the skin and subcutaneous tissues
Uncommon – short-term burning, tingling in areas where the drug was applied, slight dryness or flaking, itching;
Rarely – redness; contact dermatitis after application, more often associated with a reaction to excipients than to acyclovir.
Immune system disorders
Very rarely – immediate hypersensitivity reactions, including angioedema, urticaria.

If the side effects indicated in the instructions are observed or they get worse, or if any other side effects not listed in the instructions are detected, you should consult a doctor.

Interaction

When used externally, no interactions with other drugs have been identified.

Overdose

Due to minimal systemic exposure, undesirable effects are not expected to occur when taken orally or when applied topically to the entire contents of the consumer package of Herperax ointment. You should consult a doctor if you suspect an overdose.

Storage conditions

In a dry place, at a temperature not exceeding 25 °C.

Shelf life

3 years.

Manufacturer

Micro Labs Ltd, India